ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: A systematic review and meta-analysis

Pharmacogenomics Journal

Volumn 15, Issue 2, 2015, Pages 127-134

  Zheng, Q ^a   Wu, H ^b   Yu, Q ^b   Kim, D H ^c   Lipton, J H ^c   Angelini, S ^d   Soverini, S ^d   Vivona, D ^e   Takahashi, N ^f   Cao, J ^a  

^a THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

^f AKITA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; CYTARABINE; CYTOSINE; IMATINIB; INTERFERON; MULTIDRUG RESISTANCE PROTEIN 1; THYMINE; ABCB1 PROTEIN, HUMAN; MULTIDRUG RESISTANCE PROTEIN; PROTEIN KINASE INHIBITOR;

ABCB1 GENE; ALLELE; ARTICLE; ASIAN; CHRONIC MYELOID LEUKEMIA; DRUG METABOLISM; DRUG RESPONSE; DRUG TRANSPORT; GENOTYPE; HUMAN; META ANALYSIS; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; TREATMENT RESPONSE; ADOLESCENT; ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CHILD; GENE FREQUENCY; GENETICS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; PRESCHOOL CHILD; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; CHILD; CHILD, PRESCHOOL; GENE FREQUENCY; GENOTYPE; HUMANS; IMATINIB MESYLATE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; P-GLYCOPROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN KINASE INHIBITORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84925591777     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2014.54     Document Type: Article

References (47)

1. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984; 36: 93-99.
2. Bhamidipati PK, Kantarjian H, Cortes J, Cornelison AM, Jabbour E. Management of imatinib-resistant patients with chronic myeloid leukemia. Ther Adv Hematol 2013; 4: 103-117.
3. Etienne G, Dulucq S, Nicolini FE, Morisset S, Fort MP, Schmitt A et al. Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy. Haematologica 2014; 99: 458-464.
4. Rosti G, Castagnetti F, Gugliotta G, Palandri F, Baccarani M. Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase. Crit Rev Oncol Hematol 2012; 82: 159-170.
5. Szakacs G, Varadi A, Ozvegy-Laczka C, Sarkadi B. The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discov Today 2008; 13: 379-393.
6. Diamond JM, Melo JV. Mechanisms of resistance to BCR-ABL kinase inhibitors. Leuk Lymphoma 2011; 52(Suppl 1):12-22.
7. Hegedus T, Orfi L, Seprodi A, Varadi A, Sarkadi B, Keri G. Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochim Biophys Acta 2002; 1587: 318-325.
8. Widmer N, Colombo S, Buclin T, Decosterd LA. Functional consequence of MDR1 expression on imatinib intracellular concentrations. Blood 2003; 102: 1142.
9. Gurney H, Wong M, Balleine RL, Rivory LP, McLachlan AJ, Hoskins JM et al. Ima-tinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype. Clin Pharmacol Ther 2007; 82: 33-40.
10. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 2007; 315: 525-528.
11. Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W. Multidrug resistance poly-peptide 1 (MDR1, ABCB1) variant 3435C4T affects mRNA stability. Pharmaco-genet Genomics 2005; 15: 693-704.
12. Dulucq S, Bouchet S, Turcq B, Lippert E, Etienne G, Reiffers J et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2008; 112: 2024-2027.
13. Dulucq S, Preudhomme C, Guilhot F, Mahon FX. Response Is there really a relationship between Multidrug Resistance Gene (MDR1) polymorphisms and major molecular response to imatinib in chronic myeloid leukemia?. Blood 2010; 116: 6145-6146.
14. Deenik W, van der Holt B, Janssen JJ, Chu IW, Valk PJ, Ossenkoppele GJ et al. Polymorphisms in the multidrug resistance gene MDR1 (ABCB1) predict for molecular resistance in patients with newly diagnosed chronic myeloid leukemia receiving high-dose imatinib. Blood 2010; 116: 6144-6145.
15. Maffioli M, Camos M, Gaya A, Hernandez-Boluda JC, Alvarez-Larran A, Domingo A et al. Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia. Leuk Res 2011; 35: 1014-1019.
16. Takahashi N, Miura M, Scott SA, Kagaya H, Kameoka Y, Tagawa H et al. Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia. J Hum Genet 2010; 55: 731-737.
17. Lu PH, Yang J, Li C, Wei MX, Shen W, Shi LP et al. Association between mitogen-activated protein kinase kinase kinase 1 rs889312 polymorphism and breast cancer risk: evidence from 59, 977 subjects. Breast Cancer Res Treat 2011; 126: 663-670.
18. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-748.
19. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
20. Cochran WG. The combination of estimates from different experiments. Biometrics 1954; 10: 101-129.
21. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
22. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
23. Kim DH, Kong JH, Byeun JY, Jung CW, Xu W, Liu X et al. The IFNG (IFN-gamma) genotype predicts cytogenetic and molecular response to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res 2010; 16: 5339-5350.
24. Ni LN, Li JY, Miao KR, Qiao C, Zhang SJ, Qiu HR et al. Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia. Med Oncol 2011; 28: 265-269.
25. Chen WW, Meng FY, Zhong JS, Yin CX, Wang ZX. Effects of hOCT1 and ABCB1 gene on the efficacy of imatinib mesylate in chronic myelocytic leukemia. Zhonghua Yi Xue Za Zhi 2012; 92: 1405-1408.
26. Vivona D, Bueno CT, Lima LT, Hirata RD, Hirata MH, Luchessi AD et al. ABCB1 haplotype is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib. Blood Cells Mol Dis 2012; 48: 132-136.
27. Angelini S, Soverini S, Ravegnini G, Barnett M, Turrini E, Thornquist M et al. Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. Haematologica 2013; 98: 193-200.
28. Elghannam DM, Ibrahim L, Ebrahim MA, Azmy E, Hakem H. Association of MDR1 gene polymorphism (G2677T) with imatinib response in Egyptian chronic myeloid leukemia patients. Hematology 2013; 19: 123-128.
29. Seong SJ, Lim M, Sohn SK, Moon JH, Oh SJ, Kim BS et al. Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients. Ann Oncol 2013; 24: 756-760.
30. Milojkovic D, Apperley J. Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia. Clin Cancer Res 2009; 15: 7519-7527.
31. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251-2259.
32. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362: 2260-2270.
33. Mahon FX, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, Reiffers J et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003; 101: 2368-2373.
34. Assef Y, Rubio F, Colo G, del Monaco S, Costas MA, Kotsias BA. Imatinib resistance in multidrug-resistant K562 human leukemic cells. Leuk Res 2009; 33: 710-716.
35. Eadie LN, Hughes TP, White DL. Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib. Clin Pharmacol Ther 2014; 95: 294-306.
36. Burger H, van Tol H, Boersma AW, Brok M, Wiemer EA, Stoter G et al. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 2004; 104: 2940-2942.
37. Cortes JE, Egorin MJ, Guilhot F, Molimard M, Mahon FX. Pharmacokinetic/phar-macodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia. Leukemia 2009; 23: 1537-1544.
38. Yamakawa Y, Hamada A, Nakashima R, Yuki M, Hirayama C, Kawaguchi T et al. Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit 2011; 33: 244-250.
39. Gardner ER, Burger H, van Schaik RH, van Oosterom AT, de Bruijn EA, Guetens G et al. Association of enzyme and transporter genotypes with the pharmacoki-netics of imatinib. Clin Pharmacol Ther 2006; 80: 192-201.
40. Petain A, Kattygnarath D, Azard J, Chatelut E, Delbaldo C, Geoerger B et al. Population pharmacokinetics and pharmacogenetics of imatinib in children and adults. Clin Cancer Res 2008; 14: 7102-7109.
41. Kim DH, Sriharsha L, Xu W, Kamel-Reid S, Liu X, Siminovitch K et al. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res 2009; 15: 4750-4758.
42. Zu B, Li Y, Wang X, He D, Huang Z, Feng W. MDR1 gene polymorphisms and imatinib response in chronic myeloid leukemia: a meta-analysis. Pharmacoge-nomics 2014; 15: 667-677.
43. Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K. A comprehensive review of genetic association studies. Genet Med 2002; 4: 45-61.
44. Dick DM. Gene-environment interaction in psychological traits and disorders. Annu Rev Clin Psychol 2011; 7: 383-409.
45. Button KS, Ioannidis JP, Mokrysz C, Nosek BA, Flint J, Robinson ES et al. Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci 2013; 14: 365-376.
46. Fung KL, Gottesman MM. A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim Biophys Acta 2009; 1794: 860-871.
47. Vivona D, Lima LT, Rodrigues AC, Bueno CT, Alcantara GK, Barros LS et al. ABCB1 haplotypes are associated with P-gp activity and affect a major molecular response in chronic myeloid leukemia patients treated with a standard dose of imatinib. Oncol Lett 2014; 7: 1313-1319.